Showing results (141-150 of 332) with videos related to

Sort By:
Pageof 34
American Journal of Hematology|January 1, 2019
Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantationCatherine J Lee, Myriam Labopin, Dietrich Beelen, et al.
Clinical Hematology International|October 1, 2021
Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: <i>In vivo</i> T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant StudyAli Bazarbachi, Myriam Labopin, Giorgia Battipaglia, et al.
Blood|January 24, 2012
Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL studyPatrice Chevallier, Nelly Robillard, Aude Charbonnier, et al.
British Journal of Haematology|April 10, 2021
Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemiaMohamed A Kharfan-Dabaja, Myriam Labopin, Eolia Brissot, et al.
American Journal of Hematology|April 17, 2021
Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)Laure Philippe Walter, Lucile Couronné, Jean-Philippe Jais, et al.
Haematologica|June 22, 2014
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trialPatrice Chevallier, Myriam Labopin, Gérard Socié, et al.
Transplantation|March 14, 2015
Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular TherapyJordan Gauthier, Gandhi Damaj, Carole Langlois, et al.
Annals of Hematology|May 18, 2020
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real lifeClara Sortais, Anne Lok, Benoit Tessoulin, et al.
Bone Marrow Transplantation|January 17, 2018
Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working PartyStephen P Robinson, Ariane Boumendil, Herve Finel, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Tomasz Czerw, et al.
Pageof 34